Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy

The pro-oncogenic activities of estrogen receptor alpha (ERα) drive breast cancer pathogenesis. Endocrine therapies that impair the production of estrogen or the action of the ERα are therefore used to prevent primary disease metastasis. Although recent successes with ERα degraders have been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Mengwu, Solozobova, Valeria, Kuznik, Nane C., Jung, Nicole, Gräßle, Simone, Gourain, Victor, Heneka, Yvonne M., Cramer von Clausbruch, Christina A., Fuhr, Olaf, Munuganti, Ravi S. N., Maddalo, Danilo, Blattner, Christine, Neeb, Antje, Sharp, Adam, Cato, Laura, Weiss, Carsten, Jeselsohn, Rinath M., Orian-Rousseau, Veronique, Bräse, Stefan, Cato, Andrew C. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373600/
https://www.ncbi.nlm.nih.gov/pubmed/37520743
http://dx.doi.org/10.1158/2767-9764.CRC-23-0111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373600/
https://www.ncbi.nlm.nih.gov/pubmed/37520743
http://dx.doi.org/10.1158/2767-9764.CRC-23-0111

Ejemplares similares